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The importance of TNF-alpha in arthritis is well documented. It may be that TNF-alpha is also markedly involved in muscle
inﬂammation (myositis). An animal model where this can be investigated is needed. A newly developed rabbit myositis model
involving pronounced muscle overuse and local injections of substances having proinﬂammatory eﬀects was therefore used in the
present study. The aim was to investigate the patterns of TNF-alpha expression in the developing myositis and to evaluate the
usefulness of this myositis model for further TNF-alpha research. Human rheumatoid arthritis (RA) synovial tissue was examined
as a reference. TNF-alpha immunoexpression and TNF-alpha mRNA, visualized via in situ hybridization, were detected in cells in
the inﬂammatory inﬁltrates of the aﬀected muscle (soleus muscle). Coexistence of TNF-alpha and CD68 immunoreactions was
noted, suggesting that the TNF-alpha reactive cells are macrophages. Expression of TNF-alpha mRNA was also noted in muscle
ﬁbers and blood vessel walls in areas with inﬂammation. These ﬁndings demonstrate that TNF-alpha is highly involved in the
myositis process. The model can be used in further studies evaluating the importance of TNF-alpha in developing myositis.
1.Introduction
Tumournecrosisfactoralpha(TNF-alpha)isoneofthemost
frequently studied pro-inﬂammatory cytokines. It drives the
activation and recruitment of inﬂammatory cells, ampliﬁes
the production of other pro-inﬂammatory cytokines, and
activates nuclear transcription factors, thereby promoting
and maintaining the inﬂammatory response [1]. TNF-alpha
is likely to be a key cytokine in several autoimmune diseases
such as rheumatoid arthritis (RA), inﬂammatory bowel dis-
ease, systemic sclerosis, and systemic lupus erythematosus
[1–3].
A very large number of studies have been performed in-
vestigating the importance of TNF-alpha in arthritis, espe-
cially RA. TNF-alpha has also attracted interest in recent
years for its possible role in skeletal muscle damage. Increas-
ed protein degradation, as well as decreased body weight
and food consumption, was demonstrated when TNF-alpha
was administered to rats via a catheter into the external
jugular vein [4]. Crush injury in mice leads to elevated TNF-
a l p h al e v e l si ns k e l e t a lm u s c l et i s s u e[ 5] and there is an
increase in TNF-alpha serum levels in response to repetitive
strain injuries [6]. However, the experiments that have been
performed have sometimes yielded apparently conﬂicting
results. For example, an experiment in which TNF-alpha
was administered to mice via an osmotic pump led to accu-
mulation of inﬂammatory cells in skeletal muscles but no
signs of atrophy or injury [7]. Furthermore, the results of
studies on TNF receptor knockout and TNF-alpha antibody-
neutralized mice indicate that TNF-alpha can actually be
involved in the recovery of muscle function after traumatic
muscleinjury[8].Therefore,itmightbethattheroleofTNF-
alpha in muscle injury varies with the type, severity, and
stage of the injury [9]. In humans, TNF-alpha is known to
be intimately involved in cachexia [10], a complex condition
characterised by progressive muscle loss that aﬀects up to
13% of patients with RA [11]. Nevertheless, a recent study
showedacuteelevationofTNF-alphanottoaﬀectmarkersof
systemic or skeletal muscle turnover in healthy humans [12].
Remarkably little data is available on the role of TNF-
alpha in situations where there is a pronounced inﬁltration2 International Journal of Rheumatology
Table 1: Summary of the ﬁve subgroups of animals analyzed. The number of animals for which soleus specimens were analysed is shown.
Subgroups 3–5 had been given pro-inﬂammatory substances/endopeptidase inhibitors in combination with exercise. The subgroups 1 and
2 are collectively referred to as comprising the “nonmyositis group” and those of subgroups 3–5 as comprising the “myositis group” in the
text.
Subgroup Exercise Injection Number of animals
1N o — 6
2Y e s N a C l 5
3 Yes Substance PCaptoprilDL-Thiorphan 5
4 Yes CaptoprilDL-Thiorphan 6
5Y e s C a p t o p r i l 6
of inﬂammatory cells in the muscle tissue, that is, myositis.
From studies in tissue other than muscle, it is known that
macrophages and other immunoactive cells such as mono-
cytes, mast cells, and neutrophils are responsible for TNF-
alpha production [13–16]. Data addressing a possible TNF-
alpha production by inﬂammatory cells in myositis comes
almost entirely from studies of patients aﬀected by a group
of diseases known as “idiopathic inﬂammatory myopathies”
(inﬂammatorymyopathies)[17,18].Theseautoimmunedis-
eases include mainly the subgroups inﬂammatory myopathic
polymyositis, dermatomyositis, and inclusion body myositis
[19]. In these conditions, inﬂammatory cell-related TNF-
alpha expression is localised predominantly to macrophages
[18]. TNF-alpha is also expressed in the inﬂammatory
cells in crush-injured and transplanted muscle autografts in
mice [7]. Finally, blockade of TNF-alpha in the dystrophic
(mdx) mouse, which is the most frequently used model
of Duchenne’s muscular dystrophy, reduces TNF-mediated
adverse responses to exercise-induced muscle damage [20,
21]. However, without further information, it is diﬃcult to
reach conclusions on the importance of TNF-alpha and the
possible usefulness of TNF-blocking in muscle disorders,
includinginmyositis[22].Furthermore,itshouldbestressed
that the majority of information on the TNF system for
skeletal muscle tissue has come from studies of cultured
myoblasts (e.g., [23]). Animal models are needed to advance
our understanding of the disease mechanisms of TNF-alpha
that are involved in myositis.
Our laboratory has developed a rabbit model of marked
muscle (m. triceps surae) and tendon overuse that, when
combined with injections of substances eliciting pro-inﬂam-
matory eﬀects, results in signiﬁcant myositis [24]. This mod-
el causes myositis that morphologically resembles that seen
in inﬂammatory myopathies [17, 18] but without having an
apparent autoimmune origin. The types of white blood cells
involved in the inﬂammatory inﬁltrates were deﬁned [24].
The model leads to a muscle pathology that to some extent
resembles the morphology seen in overuse musculoskeletal
disorders (see [25], for a review, see [26]). In studies using
this model, we noted evidence of local glutamate signaling
in the cells of the inﬂammatory inﬁltrates within the muscle
tissue [24]. We have taken advantage of this model in order
to examine the TNF-system during myositis development.
Thus, the aim of this study was to examine the pattern of
TNF-alpha expression in one segment of the triceps sur-
sae muscle (the soleus muscle) aﬀected by myositis using
immunohistochemistry and in situ hybridization in order to
get an insight into the possible usefulness of this model for
further studies on the importance of TNF-alpha in myositis.
2.MaterialandMethods
2.1. Animals and Experimental Procedures
2.1.1. Animals. Twenty-eight adult female New Zealand
white rabbits were used for the studies. The animals had an
average weight of 4kg and ranged in age from 6 to 9 months.
The animals were kept in ordinary cages allowing good free-
dom of movement.
Six of the animals corresponded to control nonexercised
animals (subgroup 1) and 22 were assigned to an exercise
protocol leading to marked overuse of the triceps surae mus-
cle (subgroups 2–5). In order to increase the muscle aﬀec-
tion, including the degree of inﬂammation, the muscle over-
use was combined with paratendinous injection treatment
(cf. the following). As a control for this, ﬁve of the exercised
animals (subgroup 2) were given control substance (NaCl)
just outside the tendon of the triceps surae muscle (i.e., the
Achilles tendon). In essence, these ﬁve animals did not de-
velop myositis (Song et al., unpublished observations). For
the purpose of achieving muscle inﬂammation, 17 of the ex-
ercised animals (subgroups 3–5) were in parallel to being
subjectedtomarkedoveruse,givenlocalinjectionsofpro-in-
ﬂammatory substance (substance P and/or endopeptidase
inhibitors; Captopril, DL-Thiorphan) outside the Achilles
tendon. Substance P was given as this neuropeptide has well-
known pro-inﬂammatory eﬀects [27] and the injections of
the endopeptidase inhibitors were given in order to diminish
endopeptidase activities and thereby lead to more pro-
nounced eﬀects of substance P.
For clariﬁcation of all the various animal groups, see
Table 1.
2.1.2. Exercise Procedure. The animals were exposed to an
exercise procedure designed to cause marked overuse of the
triceps surae muscle and the associated tendon (the Achilles
tendon).Theprocedureisperformedaccordingtopreviously
described procedures [28], with some modiﬁcations [29].
Throughout the experiment, the rabbits were kept under
anaesthesia, induced by intramuscular (i.m.) injections of
diazepam (5mg/mL; 0.2mL/kg) and fentanylﬂuanison (0.2-
0.3mL/kg). Fentanylﬂuanison (0.1mL/kg) was injected eachInternational Journal of Rheumatology 3
30–45min during the experiment in order to maintain the
anaesthesia.Eachexperimentalsessionlastedfor2hours.For
analgesia, buprenorphine (0.03mg/kg) was given subcutan-
eously (s.c.) after each experiment session. The experiment
was repeated every second day for one week (4 exercise ses-
sions in total).
An apparatus (kicking machine) was used to achieve
passive repetitive ﬂexions and extensions of the right ankle
joint; a pneumatic piston attached to the right foot produced
the movements. During the plantar ﬂexion, an active con-
traction was furthermore induced by electrical stimulation
via surface electrodes (Pediatric electrode 40426A, Hewlett
Packard, Andover, MA, USA) placed 2cm apart over the
triceps surae muscle of the right leg. The stimulation was
synchronized with the plantar ﬂexion movement of the
piston by a microswitch, which trigged the stimulator unit
(Disa stimulator Type 14E10, Disa Elektronik A/S, Herlev,
Denmark). An impulse of 0.2ms duration was delivered
85ms after the initiation of the plantar ﬂexion at an ampli-
tude of 35–50V. The movement frequency was 150 repeti-
tions per minute. The left leg was not attached to the kicking
machine. The pelvis was strapped down and there were no
ankle movements on the left side. One day after the ﬁnal
exercise session, the animals were sacriﬁced by an overdose
of Pentobarbital. For further details about the apparatus and
the exercise protocol, see [24, 28–30].
2.1.3. Injection Treatments. Injections were given into the
loose connective tissue around the Achilles tendon, that is,
in the paratenon region. The injections were given directly
after each of the 2-hour exercise periods. The substances
injectedwere(a)NaCl(0.91%w/v,volume:1mL)(subgroup
2; n = 5), (b) Substance P (10−8μmol/mL) and Captopril
(Sigma) (c4042, 30μmol/kg) both in distilled water (volume:
1mL) and Dl-Thiorphan (N-[(RS)-2-Benzyl-3-mercapto-
propanoyl]-glycine) (Sigma) (500μg/mL; 0.02mL) (sub-
group 3; n = 5), (c) Captopril (Sigma) (c4042, 30μmol/kg,
dissolved in distilled water, volume 1mL) + DL-Thiorphan
(Sigma) (500μg/mL, 0.02mL) (subgroup 4; n = 6), and
(d) Captopril (Sigma) alone (c4042, 30μmol/kg, dissolved in
distilled water, volume 1mL) (subgroup 5; n = 6). For fur-
ther details, see Table 1.
2.1.4. Grouping of the Animals. Based on recent observations
in our group (Song et al., unpublished observations) and as
recently reported [24], it has become obvious that subgroups
3–5 develop myositis. Therefore, these subgroups were
grouped together and further on referred to as the “myositis
group”. As there are minimal or no signs of myositis in the
NaCl-treated subgroup (subgroup 2), the animals in this
group were grouped together with the nonexercised animals
(subgroup 1), comprising the “non-myositis group”.
2.1.5. Collection of Muscle Samples: Sectioning
Muscle Samples. After the animals were sacriﬁced, the right
triceps surae muscle was dissected out and immediately
transported on ice to the laboratory. Samples conforming
to the soleus muscle part (5–8 × 10mm) were dissected
out and ﬁxed by immersion overnight at 4◦Ci na ni c e -
cold solution of 4% formaldehyde in 0.1M phosphate buﬀer
(pH 7.0). The samples were thereafter thoroughly washed in
Tyrode’s solution containing 10% sucrose at 4◦C overnight,
mounted on thin cardboard in OCT embedding medium
(Miles Laboratories, Naperville, Ill, USA), frozen in propane
chilled with liquid nitrogen, and stored at −80◦C. Series of
5μm thick sections were cut using a cryostat. The sections
were mounted on slides precoated with chrome-alum gela-
tine and were then processed for immunohistochemistry.
Other sections were processed for morphology or in situ
hybridization.
2.1.6. Human RA Tissue Studied in Parallel. As a reference,
human RA synovial tissue was analyzed. The tissue was ﬁxed
and further processed in the same way as were the rabbit
specimens (cf. the following).
2.2. Processing for Immunohistochemistry and Morphology
2.2.1.StainingforDemonstrationofMorphology. Onesection
from all specimens was stained in Harris Haematoxylin
solution for 2min. These sections were then rinsed in
distilled water, dipped in 0.1% acetic acid for a few seconds,
and then washed in running water. Counterstaining was
achieved by immersion in eosin for 1min. The sections were
dehydrated in ethanol and mounted in Permount.
2.2.2. Immunohistochemistry. Sections of all specimens were
processed for immunohistochemistry. The sections were
pretreated with acid potassium for 2min, a procedure
found to enhance speciﬁc immunoﬂuorescence reactions
[31]. Thereafter followed incubation for 20min in a 1%
solution of Triton X-100 (Kebo lab, Stockholm) in 0.01M
phosphate buﬀer saline (PBS), pH 7.2, containing 0.1%
sodium azide as preservative, and three 5min washes in PBS.
The sections were then incubated for 15min in 5% normal
donkey serum (code no: 017-000-121, Jackson Immune
Research Lab. Inc.) in PBS. Next, incubation with the
primary antibody, diluted in PBS (pH 7.4), occurred in a
humid environment for 60min at 37◦C. After incubation
with speciﬁc antiserum, and three 5min washes in PBS,
another 15min incubation in normal donkey serum fol-
lowed. Next, the sections were incubated with either of these
donkey antigoat IgGs for 30min at 37◦: FITC-(ﬂuorescein
isothiocyanate-) conjugated AﬃniPure donkey antigoat IgG
(Jackson ImmunoResearch Lab Inc, dilution 1:100) or
Alexa FluorO 488 donkey antigoat (Invitrogen, dilution
1:300). The sections were thereafter washed in PBS and
then mounted in Vectashield Mounting Medium (H-1000)
(Vector Laboratories, Burlingame, CA, USA). Examination
w a sc a r r i e do u ti naZ e i s sA x i o s c o p e2p l u sm i c r o s c o p e
equipped with epiﬂuorescence optics and an Olympus DP70
digital camera.
2.2.3.DoubleStainings. ToclarifytheTNF-alphaimmunore-
action pattern in relation to that of white blood cells,4 International Journal of Rheumatology
double stainings were made. As it is frequently emphasized
that macrophages [13, 16] show TNF-alpha expression,
double stainings for TNF-alpha/macrophage marker (CD68)
were performed. Double stainings for TNF-alpha/T-cell-
neutrophil marker were also performed.
Alexa FluorO donkey antigoat was used as secondary
antibody for TNF-alpha immunolabelling, and TRITC (tet-
ramethylrhodamine isothiocyanate-) conjugated rabbit anti-
mouse antibody was used for stainings for CD68 and T-
cell/neutrophil marker. For detailed information about the
staining procedures for TNF-alpha, see above. When doing
double stainings for CD68 and T-cell/neutrophil marker, 5%
normal rabbit serum (code no: X0902, DAKO Cytomation,
Glostrup, Denmark), diluted in 0.1% BSA (bovine ser-
umalbumin)inPBS,wasusedasnormalserum,andTRITC-
conjugated rabbit antimouse antibody (R0276, DAKO Cyto-
mation), diluted 1:40 in 0.1% BSA in PBS, as the secondary
antibody.
2.2.4. TNF-Alpha Antibody and Control Stainings. An anti-
body against TNF-alpha produced in goats was used (AF-
210-NA; R&D Systems). Various dilutions were trialled to
achieve the optimal ﬂuorescence to background ratio, with
a dilution of 1:50 found to be optimal. The supplier reports
that this antibody is directed against E. coli-derived recom-
binant human TNF-alpha. The TNF-alpha-speciﬁc IgG was
puriﬁed by human TNF-alpha aﬃnity chromatography. It is
described to be speciﬁc via having the ability to neutralize
the biological activity of recombinant human TNF-alpha.
Of note, the TNF-alpha amino acid sequence homology
between species is reported to be highly conserved and TNF-
alpha DNA sequence comparison shows an overall high seq-
uence homology between various species (including rabbit)
[32].
In control stainings, preabsorption of the primary anti-
bodywithTNF-alphaantigen(T6674;Sigma;20μg/mLanti-
serum) was performed overnight at 4◦C. Control staining
also included staining when the primary antibody was
omitted.
2.2.5. Antibodies against CD68 and T-Cell/Neutrophil Marker
and Reference Concerning Double Stainings. Am a c r o p h a g e
(CD68) antibody (M0814) from DAKO Cytomation (Glos-
trup, Denmark) was used. It is an aﬃnity puriﬁed mouse
monoclonal antibody and was used at a dilution of 1:100
in 0.1% BSA in PBS. The antigen for this antibody is glycosy-
lated transmembrane glycoprotein, which is mainly located
in lysosomes. A mouse antirabbit T-cell and neutrophil anti-
body (MCA805G) from AbD Serotec (Oxford, UK) was fur-
thermore used. It is an aﬃnity puriﬁed mouse monoclonal
antibody against a cell surface antigen, which is expressed
by a subset of T-cells, thymocytes, neutrophils, and plate-
lets in rabbits. The dilution was 1:100 in 0.1% BSA in PBS.
Stainings performed in a parallel project on rabbit soleus
muscle [24] were used as a reference (control) for the current
double stainings. In that project, double stainings were per-
formed using the same CD68 and T-cell/neutrophil mark-
er antibodies as in the current double stainings. In this pre-
vious study, double stainings were made against an antibody
produced in goats (against VGluT2; Santa Cruz), that is,
beingofthesametypeastheTNF-alphaantibodyusedinthe
current study. In these reference stainings, the same types of
secondary antibodies as described previously were utilized.
3. Processingfor InSitu Hybridization
In situ hybridization was used as a complementary method
to detect the expression of TNF-alpha, namely, at the
mRNAlevel.Adigoxigenin-(DIG)hyperlabeledoligonucleo-
tide probe (ssDNA) for detection of rabbit TNF-alpha
mRNA was used on sections from myositis (4 specimens)
and nonmyositis (1 specimen) groups (GD1001-DS custom
designed; GeneDetect, New Zealand). The antisense seq-
uence of the probe was CGGCGAAGCGGCTGACAGTG-
TGAGTGAGGAGCACGTAGGAGCGGCAGC. The proce-
dures were performed according to an established protocol
[33], using an alkaline phosphatase-labeled anti-DIG anti-
body for detection [34]. The probe for TNF-alpha mRNA
was used at 50ng in 15μL of hybridization solution.
The tissue specimens were cut into 10μm thick fresh
cryosections using a cryostat (with a knife washed in 70%
EtOH in DEPC [diethylpyrocarbonate]-H2O) and mounted
onto Super Frost Plus slides (nr.041200, Menzel Gl¨ aser). The
protocol that thereafter followed was that previously used in
our laboratory for detection of mRNA for other substances
(e.g., [34–36]).
An alkaline phosphatase-(AP) labelled anti-DIG anti-
body (Roche, Germany, 11 093 274 910) was used for detec-
tion. The sections were ﬁnally mounted in Pertex mounting
medium.
The corresponding sense DIG-hyperlabeled ssDNA pro-
bewasusedasanegative control.Asapositive controlprobe,
a β-actin antisense probe (GD5000-OP) was used, compar-
isonsbeingmadewithsenseβ-actinprobe(GeneDetect,New
Zealand).
Ethics. The study protocol was approved by the local ethical
committee at Ume˚ a University.
4. Results
4.1. Morphology. Myositis was observed in subgroups 3–
5, and these are now collectively being referred to as the
“myositis group” (cf. above). The most noteworthy feature
was the presence of an inﬂammatory inﬁltrate (Figure 1),
although muscle ﬁber changes were also observed, including
muscle ﬁber necrosis (cf. [24]). Variations in the levels of
myositis were observed between the diﬀerent subgroups,
as well as between diﬀerent animals within the subgroups.
The inﬂammatory inﬁltrates were seen in some parts of the
specimens. In the other groups (subgroups 1 and 2), there
were no or very marginal changes seen and these are now
collectively referred to as the “nonmyositis group”.
4.2. Reference Studies Concerning the TNF-Alpha Antiserum
Used. It was considered relevant to examine a reference tis-
sue regarding the demonstration of TNF-alpha. Human RAInternational Journal of Rheumatology 5
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Figure 1: Soleus muscle of a specimen of the myositis group in
a section stained with htx eosin. There is a marked inﬂammatory
inﬁltrate (middle part): myoﬁbers to the left and to the right.
synovial tissue was therefore analysed to provide reference
information for the particular TNF-alpha antibody used,
as it a well-known fact that there is a marked TNF-alpha
expression in the inﬂammatory inﬁltrates in the synovial
tissue of patients with RA [37].
We observed that mononuclear-like cells of the human
synovial tissue exhibited immunoreactions when incubated
with the TNF-alpha antiserum (Figures 2 and 3). The reac-
tions were in high magniﬁcation seen in the form of intracel-
lular granular reactions (cf. Figures 2 and 3). The speciﬁcity
ofthereactionswasconﬁrmedviapreabsorption withsynth-
eticantigen(Figure 2).Thecellsoccurredaspartsofimmune
cell aggregates or as isolated cells in the synovial tissue.
4.3. TNF Alpha Immunoreactions in the Rabbit Soleus Muscle.
Pronounced TNF-alpha immunoreactions were observed in
cells of the inﬂammatory inﬁltrates (Figures 4 and 5)i na l l
subgroups in the myositis group. It was noteworthy that the
immunoreaction patterns seen in the cells resembled those
observed for the mononuclear-like cells of the human RA
synovialtissue.Thus,thereactionsshowedagranularpattern
in high magniﬁcation (Figures 4 and 5). In lower magniﬁca-
tion, the reactions were of a more diﬀu s et y p e( Figure 6(a)).
The speciﬁcity of the reactions was veriﬁed via preabsor-
ptions (Figure 4).
Fibroblasts in the connective tissue did also to some
extent display TNF-alpha immunoreactions, however the
reactions were very faint. No speciﬁc TNF-alpha reactions
were noted for blood vessel walls, the nerve fascicles, muscle
spindles, and the muscle ﬁbers (not shown).
4.4. Results of Double Stainings. In order to clarify the pat-
ternsofcellularreactionsforTNF-alphaintheinﬂammatory
inﬁltrates, double stainings for TNF-alpha/CD-68 and TNF-
alpha/T cells and neutrophil marker were performed. It
was found that CD68 coexisted with TNFalpha in cells in
the inﬂammatory inﬁltrates (Figure 6). On the other hand,
colocalization between TNF-alpha and T cells and neutro-
phil marker was not observed (not shown). In the reference
studies (cf. Section 2) using the same secondary antisera
and the same white blood cell markers but a primary goat
antibody not directed against TNF-alpha, completely diﬀer-
ent colocalization patterns were noted [24].
(a)
(b)
Figure 2:(a,b)Sectionsofsynovialtissueofapatientwithrheuma-
toid arthritis. The sections were stained for demonstration of TNF-
alpha (a) and for TNF-alpha after preabsorption with TNF-alpha
antigen (b). Inﬂammatory cells show speciﬁc immunoreaction in
(a) (arrows). There are no speciﬁc immunoreactions in these in
(b) (arrows). The inﬂammatory cells had in parallel sections been
identiﬁed via staining for routine morphology (htx eosin).
 
Figure 3: Staining for demonstration of TNF-alpha in a synovial
tissue specimen of a rheumatoid arthritis patient. There are speciﬁc
reactions in inﬂammatory cells (arrows). The reactions show a
granular appearance.6 International Journal of Rheumatology
(a) (b)
Figure 4: Sections of a myositis specimen stained for TNF-alpha (a) and for TNF-alpha after preabsorption with TNF-alpha antigen (b).
The cells of an inﬂammatory inﬁltrate show immunoreactions for TNF-alpha (a) (arrows). There are no speciﬁc reactions in (b) (arrows at
some of the cells).
(a) (b)
Figure 5 :( a ,b )Secti o n so fm y o s i ti ss pec i m e n sa f t e rp r oc e s s i n gf o rT N F - a lpha. Cells showspeciﬁc immunoreactions (arrows). Thereactions
show a granular appearance.
(a) (b)
Figure 6: (a, b) Inﬂammatory inﬁltrate in a soleus muscle (myositis specimen). Double-staining for demonstration of TNF-alpha (a) and
CD68 (b). Immunoreactions are seen in the same cells (arrows).International Journal of Rheumatology 7
(a)
(b)
Figure 7: In situ hybridization for the demonstration of TNF-
alpha mRNA in inﬂammatory cells. Adjacent sections are shown:
antisense staining (a), and sense staining (b). There are reactions in
(a) but not in (b). The arrows point at inﬂammatory cells.
4.5. In Situ Hybridization. Reactions for TNF-alpha mRNA
were revealed for white blood cells of the inﬂammatory inﬁl-
trates in the myositis specimens (Figure 7). Reactions were
also seen for ﬁbroblasts (Figure 8) and sometimes for blood
vessel walls (Figure 9) and muscle ﬁbers (Figure 10). The
muscle ﬁbers and blood vessels for which reactions were seen
were located in the regions with inﬂammatory inﬁltrates. It
was noted that the muscle ﬁbers with reactions for TNF-
alpha mRNA were often inﬁltrated by inﬂammatory cells.
The majority of the muscle ﬁbers and blood vessels in the
tissue of the myositis samples had no demonstrable reaction.
There were no reactions at all in the musculature and the
blood vessel walls in the nonmyositis samples. No reactions
were noted for nerve fascicles and muscle spindles in any of
the specimens from the myositis or non-myositis groups.
5. Discussion
It is well known that TNF-alpha is highly involved in
arthritis, notably in RA. Accordingly, in our reference studies
(a)
(b)
Figure 8: In situ hybridization for the demonstration of TNF-
alpha mRNA in ﬁbroblasts. Adjacent sections are shown: antisense
staining (a), and sense staining (b). There are reactions in (a) but
not in (b). The arrows point at ﬁbroblasts.
in the present investigation we found that TNF-alpha was
expressedinmononuclear-likecellsintheRAsynovialtissue.
Detection of TNF-alpha reactions was thus clariﬁed from
the methodological point of view, and veriﬁcations were
obtained via preabsorption stainings. With this as a basis,
studies on TNF-alpha in myositis were performed.
A unique model for the production of myositis in rabbit
musculature (the soleus muscle) was utilized. The main
ﬁnding was that cells in the inﬂammatory inﬁltrates in the
myositis muscles were found to express TNF-alpha at both
at the mRNA and protein levels. Colocalization between
TNF-alpha and CD68 was noted for these cells. Expression
of TNF-alpha in macrophages has previously been noted
in other situations (e.g., [13, 16]), including inﬂammatory
myopathies [17]. In contrast, in our recent studies using
the current myositis model, expression of the vesicular
glutamate transporter VGluT2 was noted in white blood
cells in the inﬂammatory inﬁltrates other than macrophages
[24]. A further main ﬁnding was that the muscle ﬁbers and
blood vessel walls in areas showing inﬂammatory inﬁltration
exhibited TNF-alpha mRNA and that ﬁbroblasts also were
seen to exhibit TNF-alpha mRNA.
From a methodological point of view, it was clear that
muscle ﬁbers, blood vessel walls, and ﬁbroblasts exhibited
TNF-alpha mRNA but that no reactivity (muscle ﬁbers,
blood vessel walls) or very weak reactivity (ﬁbroblasts) was
noted at the protein level. The production level in these
locations is therefore likely to be low, which precluded clear
detection with our immunohistochemical methods. It is also
possible that our in situ hybridization method detects very
small quantities of TNF-alpha mRNA. Nevertheless, it has
previously been shown that TNF-alpha can be expressed not
only in inﬂammatory cells but also in injured muscle ﬁbers
and ﬁbroblasts in response to muscle injury (crush-injury)
[7] as well as in muscle ﬁbers and cells in the connective
tissue in inﬂammatory myopathies [17, 18].
The patterns of morphologic appearances of the inﬂam-
matory inﬁltrates and other morphologic changes seen
resembled the appearances that can be seen in the muscle8 International Journal of Rheumatology
(a) (b)
Figure 9: In situ hybridization for the demonstration of TNF-alpha mRNA in a small blood vessel: antisense staining (a), and sense staining
(b). The vessel was located in the proximity of an inﬂammatory inﬁltrate. Arrows point at the wall. There are reactions in the wall in (a) but
not in (b). Asterisks are in the lumen.
(a) (b)
Figure 10:InsituhybridizationforthedemonstrationofTNF-alphamRNAinthemuscletissue.Adjacentsectionsareshown,oneprocessed
with antisense probe (a), the other with sense probe (b). There are reactions in muscle ﬁbers in (a) but not in (b). Arrowheads indicate
corresponding muscle ﬁbers in (a) and (b). As veriﬁed via examinations of parallel sections processed for morphology, the reactive muscle
ﬁbers are inﬁltrated by inﬂammatory cells. Certain muscle ﬁbers appear to be unaﬀected (asterisk).
tissue in inﬂammatory myopathies [38]. Nevertheless, pre-
liminary analysis using ELISA detecting anti-Jo-1 antibodies,
which are known to correlate with disease activity for
patients with inﬂammatory myopathy [39], does not lend
proof to the theory that the myositis in our model is
autoimmune in origin (unpublished observations). How-
ever, further studies on this aspect are warranted.
As noted previously, TNF-alpha immunoreactions in
inﬂammatory cells invading muscles aﬀected by myositis
have previously only been documented in biopsies from
patients with inﬂammatory myopathies [17, 18] and in
muscleofmiceinresponsetocrush-injury[7].Thus,incom-
binationwiththispreviouswork,ourresultsimplythatTNF-
alpha is intimately involved in the inﬂammatory process in
myositis. Indeed, it has been suggested that TNF-alpha may
have a role in the pathogenesis of the myositis in the inﬂam-
matorymyopathies[40,41]andthatamarkedinﬂammatory
response involving TNF-alpha may be directly responsible
for damaging muscle ﬁbres in myopathic conditions [42].
Whether or not the TNF-alpha produced by the cells
of the inﬂammatory inﬁltrates is entirely responsible for
pro-inﬂammatory and damaging eﬀects remains open to
speculation. It is well known that TNF-alpha administration
can have pro-inﬂammatory and detrimental eﬀects, for
example, leading to various catabolic changes as seen in
studies on cultured skeletal muscle cells [4, 43, 44]. However,
there is a marked discrepancy in the literature regarding the
eﬀect of TNF-alpha on the musculature. Some studies on
myoblast cell culture show that TNF-alpha administration
does not have catabolic eﬀects (e.g., [45]), and other studies
documentingaccumulationsofinﬂammatorycellsinskeletal
muscleinresponsetoTNF-alphaadministration[4]showno
decrease in skeletal muscle proteins and no signs of muscle
atrophy or injury. Perhaps these discrepancies reﬂect a dual
role of TNF-alpha where in some circumstances inﬂamma-
tory cell derived TNF-alpha can play a protective role [46]
and also be involved in the recovery of muscle function after
traumatic injury [9] and in muscle regeneration [47]. The
discrepancies may also reﬂect the fact that diﬀerent methods
have been used in the studies that have been performed. The
results in preliminary studies on inﬂammatory myopathies
suggest that TNF blocking might be useful [48], but it is
also emphasized that further studies are needed in order
to clarify if this type of treatment is indeed useful [22].International Journal of Rheumatology 9
Results of in vitro studies suggest that targeting TNF-alpha
might be worthwhile in myositis [49, 50] and studies on
dystrophic mdx mice subjected to wheel exercise indicate
that TNF blockade can reduce myoﬁber necrosis [20, 21].
The use of anti-TNF treatment in studies on a rat model
of repetitive reaching and grasping leads to an improvement
in grip strength and attenuated task-induced increases in
inﬂammatory cytokines, including TNF-alpha [51].
Although the use of other animal models have shown
inﬂammation in muscle tissue in response to various forms
of exercise [50, 52], the myositis model used in the current
experiment is clearly distinguishable from these models.
Thus, in contrast to these models, it leads to a marked pre-
sence of inﬂammatory inﬁltrates in the muscle tissue, that is,
a morphology resembling that seen in inﬂammatory myo-
pathies. In fact, no experimental myositis model exists which
resembles the one used here and in which a marked presence
of inﬂammatory inﬁltrates becomes present in the mus-
cle tissue. Those for which such an inﬁltration has been de-
monstrated are the model of crush-injury described above
[7] and models designed to help understand the mecha-
nisms of inﬂammatory myopathies that occur in man. In
these latter cases, myositis is induced by various infectious
agents [53, 54], immunization with muscle components,
for example, myosin [55, 56], and intraperitoneal injections
with lipopolysaccharide [57]. The TNF system has not been
examined in any of these myositis models replicating the
inﬂammatory myopathies seen in man. Interestingly, there is
evidence indicating a relationship between the inﬂammatory
myopathies and another condition, muscular dystrophy, in
the form of complex interactions between immunological
and nonimmunological features of the diseases [58].
A noteworthy aspect with the currently used model is
that marked overuse is applied in the procedures. Neverthe-
less, a limitation of the present study is that the relative con-
tributions of the exercise protocol and the injections of the
proinﬂammatory substances to the observed myositis are
unclear. Forthcoming studies will clarify this issue. In any
case, the model will, as it is currently used, provide the op-
portunity to evaluate the eﬀects of interference with TNF-
alpha actions in myositis development.
6. Conclusions
An animal model in which the importance of TNF-alpha for
myositis development can be followed has previously been
lacking. Using a newly established rabbit model of myositis
development, a marked TNF-alpha expression has here been
shown for the cells of the inﬂammatory inﬁltrates within
damaged muscle. There was thus a clear evidence of local
TNF-alpha production via inﬁltrated inﬂammatory cells,
presumably leading to secondary inﬂammation-modifying
eﬀects. Using in situ hybridization, it was also seen that
TNF-alpha mRNA was detected for muscle ﬁbers and
blood vessel walls in regions of inﬂammatory inﬁltrates.
The current model can be used for further studies on the
importance of TNF-alpha in the development of myositis
and to document the expression patterns of other cytokines
and signal substances in this condition.
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